UniProtKB/SwissProt variant VAR

Variant information

Variant position:

270

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:

LP/P [Disclaimer]

The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Glycine (G) to Cysteine (C) at position 270 (G270C, p.Gly270Cys).

Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:

Change from glycine (G) to medium size and polar (C)

The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:

-3

The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page

Variant description:

In NEM3; autosomal dominant.

Any additional useful information about the variant.

Other resources:

Links to websites of interest for the variant.

Variant rs121909525 [ dbSNP | Ensembl ]

Sequence information

Variant position:

270

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:

377

The length of the canonical sequence.

Location on the sequence:

ITIGNERFRCPETLFQPSFI G MESAGIHETTYNSIMKCDID

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         ITIGNERFRCPETLFQPSFIGMESAGIHETTYNSIMKCDID

Mouse                         ITIGNERFRCPETLFQPSFIGMESAGIHETTYNSIMKCDID

Rat                           ITIGNERFRCPETLFQPSFIGMESAGIHETTYNSIMKCDID

Pig                           ITIGNERFRCPETLFQPSFIGMESAGIHETTYNSIMKCDID

Bovine                        ITIGNERFRCPETLFQPSFIGMESAGIHETTYNSIMKCDID

Rabbit                        ITIGNERFRCPETLFQPSFIGMESAGIHETTYNSIMKCDID

Chicken                       ITIGNERFRCPETLFQPSFIGMESAGIHETTYNSIMKCDID

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	2 – 377	Actin, alpha skeletal muscle, intermediate form
Chain	3 – 377	Actin, alpha skeletal muscle
Cross	272 – 272	Isoglutamyl lysine isopeptide (Glu-Lys) (interchain with K-52); by Vibrio toxins RtxA and VgrG1

Literature citations

Nemaline myopathy caused by mutations in the muscle alpha-skeletal-actin gene.
Ilkovski B.; Cooper S.T.; Nowak K.; Ryan M.M.; Yang N.; Schnell C.; Durling H.J.; Roddick L.G.; Wilkinson I.; Kornberg A.J.; Collins K.J.; Wallace G.; Gunning P.; Hardeman E.C.; Laing N.G.; North K.N.;
Am. J. Hum. Genet. 68:1333-1343(2001)
Cited for: VARIANTS NEM3 SER-117; MET-138; GLY-185; CYS-270 AND LEU-359;

Heterogeneity of nemaline myopathy cases with skeletal muscle alpha-actin gene mutations.
Agrawal P.B.; Strickland C.D.; Midgett C.; Morales A.; Newburger D.E.; Poulos M.A.; Tomczak K.K.; Ryan M.M.; Iannaccone S.T.; Crawford T.O.; Laing N.G.; Beggs A.H.;
Ann. Neurol. 56:86-96(2004)
Cited for: VARIANTS NEM3 LEU-37; LEU-40; TYR-42; ARG-43; ASN-66; LEU-75; ARG-75; LEU-77; ALA-79; LYS-85; ALA-136; ASP-148; GLY-181; ASP-184; GLY-185; SER-199; GLY-226; VAL-229; ILE-229; ARG-248; ASP-253; CYS-270; HIS-281; LYS-282; GLY-288 AND GLN-375;

Evidence for a dominant-negative effect in ACTA1 nemaline myopathy caused by abnormal folding, aggregation and altered polymerization of mutant actin isoforms.
Ilkovski B.; Nowak K.J.; Domazetovska A.; Maxwell A.L.; Clement S.; Davies K.E.; Laing N.G.; North K.N.; Cooper S.T.;
Hum. Mol. Genet. 13:1727-1743(2004)
Cited for: VARIANTS NEM3 ILE-68; LYS-74; SER-117; MET-138; LEU-165; MET-165; GLY-185; CYS-270 AND LEU-359;

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P68133: Variant p.Gly270Cys